المؤلفون: T. Kirsanova V., M. Vinogradova A., Т. Кирсанова В., М. Виноградова А.

المصدر: Meditsinskiy sovet = Medical Council; № 3 (2021); 98-105 ; Медицинский Совет; № 3 (2021); 98-105 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: thrombotic microangiopathy, HELLP syndrome, atypical hemolytic-uremic syndrome, thrombocytopenic purpura, eculizumab, тромботическая микроангиопатия, HELLP-синдром, атипичный гемолитико-уремический синдром, тромбоцитопеническая пурпура, экулизумаб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6079/5539; Fakhouri F., Zuber J., Fremeaux-Bacchi V., Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681-696. doi:10.1016/S0140-6736(17)30062-4.; George J.N., Nester C.M., McIntosh JJ. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hematol Educ Program. 2015;2015:644-648. doi:10.1182/asheducation-2015.1.644.; George J.N., Nester C.M. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654-666. doi:10.1056/NEJMra1312353.; Кирсанова Т.В., Виноградова М.А., Федорова ТА. Имитаторы тяжелой преэклампсии и HELL-синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью. Акушерство и гинекология. 2016;(12):5-14 doi:10.18565/aig.2016.12.5-14.; Brown M.A., Magee L.A., Kenny L.C., Karumanchi S.A., McCarthy F.P., Saito S. et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24-43. doi:10.1161/HYPERTENSIONAHA.117.10803.; Mol B.W. J., Roberts C.T., Thangaratinam S., Magee L.A., de Groot CJ.M., Hofmeyr GJ. Preeclampsia. Lancet. 2016;387(10022):999-1011. doi:10.1016/S0140-6736(15)00070-7.; Liu J., Ghaziani T.T., Wolf J.L. Acute fatty liver disease of pregnancy: updates in pathogenesis, diagnosis, and management. Am J Gastroenterol. 2017;112(6):838-846. doi:10.1038/ajg.2017.54.; Silver R.M. Catastrophic antiphospholipid syndrome and pregnancy. Semin Perinatol. 2018;42(1):26-32. doi:10.1053/j.semperi.2017.11.006.; Burlinson C.E. G., Sirounis D., Walley K.R., Chau A. Sepsis in pregnancy and the puerperium. Int J Obstet Anesth. 2018;36:96-107. doi:10.1016/j.ijoa.2018.04.010.; Fakhouri F., Scully M., Provot F., Blasco M., Coppo P, Noris M. et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020;136(19):2103-2117. doi:10.1182/blood.2020005221.; Kellum J.A., Aspelin P., Barsoum R.S., Burdmann E.A., Goldstein S.L., Herzog C.A. et al. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138. Available at: https://Www.kisupple-ments.org/issue/S2157-1716(12)X7200-9.; Fujimura Y., Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 19982008. Intern Med. 2010;49(1):7-15. doi:10.2169/internalmedicine.49.2706.; Mariotte E., Azoulay E., Galicier L., Rondeau E., Zouiti F., Boisseau P et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(5):e237-e245. doi:10.1016/S2352-3026(16)30018-7.; Zheng X.L., Vesely S.K., Cataland S.R., Coppo P, Geldziler B., Iorio A. et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2486-2495. doi:10.1111/jth.15006.; Mackie I., Mancini I., Muia J., Kremer Hovinga J., Nair S., Machin S., Baker R. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. Int J Lab Hematol. 2020;42(6):685-696. doi:10.1111/ijlh.13295.; Moatti-Cohen M., Garrec C., Wolf M., Boisseau P, Galicier L., Azoulay E. et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888-5897. doi:10.1182/blood-2012-02-408914.; Delmas Y., Helou S., Chabanier P., Ryman A., Pelluard F., Carles D. et al. Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease. BMC Pregnancy Childbirth. 2015;15(1):137. doi:10.1186/s12884-015-0557-5.; Lattuada A., Rossi E., Calzarossa C., Candolfi R., Mannucci P.M. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003;88(9):1029-1034. Available at: https://pub-med.ncbi.nlm.nih.gov/12969811/.; Stepanian A., Cohen-Moatti M., Sanglier T., Legendre P, Ameziane N., Tsatsaris V. et al. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. Arterioscler Thromb Vasc Biol. 2011;31(7):1703-1709. doi:10.1161/ATVBAHA.111.223610.; Bayer G., von Tokarski F., Thoreau B., Bauvois A., Barbet C., Cloarec S. et al. Etiology and outcomes of thrombotic microangiopathies. Clin J Am Soc Nephrol. 2019;14(4):557-566. doi:10.2215/CJN.11470918.; Bruel A., Kavanagh D., Noris M., Delmas Y., Wong E.K. S., Bresin E. et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol. 2017;12(8):1237-1247. doi:10.2215/CJN.00280117.; Fakhouri F., Roumenina L., Provot F., Sallee M., Caillard S., Couzi L. et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859-886. doi:10.1681/ASN.2009070706.; Huerta A., Arjona E., Portoles J., Lopez-Sanchez P, Rabasco C., Espinosa M. et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018;93(2):450-459. doi:10.1016/j.kint.2017.06.022.; Rehberg J.F., Briery C.M., Hudson W.T., Bofill J.A., Martin J.N. Jr. Thrombotic thrombocytopenic purpura masquerading as hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome in late pregnancy. Obstet Gynecol. 2006;108(3 Pt. 2):817-820. doi:10.1097/01.AOG.0000215994.25958.31.; Птушкин В.В., Кулагин А.Д., Лукина Е.А., Давыдкин И.Л., Константинова Т.С., Шамрай В.С. и др. Результаты открытого многоцентрового клинического исследования Ib фазы по оценке безопасности, фармакокинетики и фармакодинамики первого биоаналога экулизумаба у нелеченых пациентов с пароксизмальной ночной гемоглобинурией в фазе индукции терапии. Терапевтический архив. 2020;92(7):77-84. doi:10.26442/00403660.2020.07.000818.; Kulagin A., Ptushkin V., Lukina E., Gapchenko E., Markova O., Zuev E., Kudlay D. Phase III clinical trial of Elizaria® and Soliris® in adult patients with paroxysmal nocturnal hemoglobinuria: results of comparative analysis of efficacy, safety, and pharmacological data. Blood. 2019;134(1 Suppl.):3748. doi:10.1182/blood-2019-125693.; Pourrat O., Coudroy R., Pierre F. ADAMTS13 deficiency in severe postpartum HELLP syndrome. Br J Haematol. 2013;163(3):409-410. doi:10.1111/bjh.12494.; Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennstrom M. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13-22. doi:10.1056/NEJMoa1414838.; Verlohren S., Herraiz I., Lapaire O., Schlembach D., Zeisler H., Calda P. et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63(2):346-352. doi:10.1161/HYPERTENSIONAHA.113.01787.; Caillon H., Tardif C., Dumontet E., Winer N., Masson D. Evaluation of sFlt-1/ PlGF ratio for predicting and improving clinical management of preeclampsia: experience in a specialized perinatal care center. Ann Lab Med. 2018;38(2):95-101. doi:10.3343/alm.2018.38.2.95.; George J.N. Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognised? Lancet. 2015;386(9997):1012. doi:10.1016/S0140-6736(15)00077-X.; Frimat M., Decambron M., Lebas C., Moktefi A., Lemaitre L., Gnemmi V. et al. Renal cortical necrosis in postpartum hemorrhage: a case series. Am J Kidney Dis. 2016;68(1):50-57. doi:10.1053/j.ajkd.2015.11.022.; Fakhouri F., Deltombe C. Pregnancy-related acute kidney injury in high income countries: still a critical issue. J Nephrol. 2017;30(6):767-771. doi:10.1007/s40620-017-0440-8.; Scully M., Thomas M., Underwood M., Watson H., Langley K., Camilleri R.S. et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211-219. doi:10.1182/blood-2014-02-553131.; Fremeaux-Bacchi V, Fakhouri F., Garnier A., Bienaime F., Dragon-Durey MA., Ngo S. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562. doi:10.2215/CJN.04760512.; Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859. doi:10.2215/CJN.02210310.; https://www.med-sovet.pro/jour/article/view/6079

الاتاحة: https://www.med-sovet.pro/jour/article/view/6079
https://doi.org/10.21518/2079-701X-2021-3-98-105

المؤلفون: M. Vinogradova A., T. Kirsanova V., D. Serebriyskaya S., М. Виноградова А., Т. Кирсанова В., Д. Серебрийская С.

المصدر: Meditsinskiy sovet = Medical Council; № 3 (2020); 68-73 ; Медицинский Совет; № 3 (2020); 68-73 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2020-3

مصطلحات موضوعية: endothelial dysfunction, sulodexide, reproductive losses, chronic venous disease, pregravid preparation, дисфункция эндотелия, сулодексид, репродуктивные потери, хроническая венозная болезнь, прегравидарная подготовка

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5572/5076; Черняховская Н.Е., Шишло В.К., Поваляев А.В. Коррекция микроциркуляции в клинической практике. М.: Бином; 2013. 208 с.; Cicinelli E., De Ziegler D., Nicoletti R., Colafiglio G., Saliani N., Resta L. et al. Chronic endometritis: correlation among hysteroscopic, histologic, and bacteriologic findings in a prospective trial with 2190 consecutive office hysteroscopies. Fertil Steril. 2008;89(3):677–684. doi:10.1016/j.fertnstert.2007.03.074.; Kimura F., Takebayashi A., Ishida M., Nakamura A., Kitazawa J., Morimune A. et al. Review: Chronic endometritis and its effect on reproduction. J Obstet Gynaecol Res. 2019;45(5):951–960. doi:10.1111/jog.13937.; Hoppensteadt D.A., Fareed J. Pharmacological profile of sulodexide. Int Angiol. 2014;33(3):229–235. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24936531.; Masola V., Zaza G., Onisto M., Lupo A., Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014;33:243–254. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24936533.; Zhang X., Sun D., Song J.W., Zullo J., Lipphardt M., Coneh-Gould L., Goligorsky M.S. Endothelial cell dysfunction and glycocalyx – A viscious circle. Matrix Biol. 2018;71–72:421–431. doi:10.1016/j.matbio.2018.01.026.; Veraldi N., Guerrini M., Urso E., Risi G., Bertini S., Bensi D., Bisio A. Fine structural characterization of sulodexide. J Pharm Biomed Anal. 2018;156:67–79. doi:10.1016/j.jpba.2018.04.012.; Coccheri S., Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013;8:49–65. doi:10.2147/DDDT.S6762.; Harenberg J. Review of pharmacodynamics, pharmacokinetics and therapeutic properties of sulodexide. Med Res. 1998;18(1):1–20. doi:10.1002/(SICI)1098-1128(199801)18:13.0.CO;2-4.; Milani M.R., Busutti L., Breccia A. Pharmacokinetics of sulodexide evaluation from 131-labelled fast-moving heparin after single intravenous and oral administration on man at different doses. Brit J Clin Res. 1992;3:161–178.; Carroll B.J., Piazza G., Goldhaber S.Z. Sulodexide in Venous Disease. J Thromb Haemost. 2019;17(1):31–38. doi:10.1111/jth.14324.; Cosmi B., Cini M., Legnani C., Pancani C., Calanni F., Coccheri S. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003;109(5–6):333–339. doi:10.1016/S00493848(03)00246-9.; Mauro M., Ferraro G., Palmieri G.C. Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double-blind, cross-over, placebocontrolled study. Curr Ther Res. 1992;51:342–350.; Cerletti C., Rajtar G., Marchi E., De Gaetano G. Interaction between glycosaminoglycans, platelets, and leukocytes. Semin Thromb Hemost. 1994;20(3):245–253. doi:10.1055/s-2007-1001909.; Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008;122(6):743–752. doi:10.1016/j.thromres.2006.10.026.; Ligi D., Croce L., Mosti G., Raffetto J.D., Mannello F. Chronic venous insufficiency: Transforming growth factor-beta isoforms and soluble endoglin concentration in different states of wound healing. Int J Mol Sci. 2017;18(10):2206. doi:10.3390/ijms18102206.; Mannello F., Ligi D., Raffetto J.D. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014;33(3):236–242. Availale at: https://www.ncbi.nlm.nih.gov/pubmed/24936532.; Mannello F., Ligi D., Canale M., Raffetto J.D. Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease. Curr Vasc Pharmacol. 2014;12(1):173–185. doi:10.2174/1570161111666131126144025.; Ciszewicz M., Polubinska A., Antoniewicz A., Suminska-Jasinska K., Breborowicz A. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res. 2009;153(3):118–123. doi:10.1016/j.trsl.2008.12.007.; Blich M., Golan A., Arvatz G., Sebbag A., Shafat I., Sabo E. et al. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol. 2013;33(2):e56– e65. doi:10.1161/ATVBAHA.112.254961.; Andreozzi G.M. Role of sulodexide in the treatment of CVD. Int Angiol. 2014;33(3):255–262.; Mannello F., Medda V., Ligi D., Raffetto J.D. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol. 2013;11(3):354–365. doi:10.2174/1570161111311030010.; Ligi D., Mosti G., Croce L., Raffetto J.D., Mannello F. Chronic venous disease – part II: Proteolytic biomarkers in wound healing. Biochim Biophys Acta (BBA). 2016;1862(10):1900–1908. doi:10.1016/j.bbadis.2016.07.011.; Meissner M.H., Eklof B., Smith P.C., Dalsing M.C., DePalma R.G., Gloviczki P. et al. Secondary chronic venous disorders. J Vasc Surg. 2007;46(6):S68S– S83. doi:10.1016/j.jvs.2007.08.048.; Chatterjee S. Endothelial mechanotransduction, redox signaling and the regulation of vascular inflammatory pathways. Front Physiol. 2018;9:1–16. doi:10.3389/fphys.2018.00524.; Bergan J.J., Schmid-Schönbein G.W., Coleridge Smith P.D., Nicolaides A.N., Boisseau M.R., Eklof B. Chronic venous disease. N Engl J Med. 2006;355:488–498. doi:10.1056/NEJMra055289.; Elleuch N., Zidi H., Bellamine Z., Hamdane A., Guerchi M., Jellazi N. Sulodexide in patients with chronic venous disease of the lower limbs: clinical efficacy and impact on quality of life. Adv Ther. 2016;33:1536– 1549. doi:10.1007/s12325-016-0359-9.; Raffetto J.D. Dermal pathology, cellular biology, and inflammation in chronic venous disease. Thromb Res. 2009;123:S66–S71. doi:10.1016/S0049-3848(09)70147-1.; Mansilha A., Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int J Mol Sci. 2018;19(6):1–21. doi:10.3390/ijms19061669.; Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008;133(6):454S–545S. doi:10.1378/chest.08-0658.; Engberink O., Rorije N.M., Lambers Heersprink H.J., Zeeuw D.D., Born van den B.-J.H., Vogt L. The blood pressure lowering potential of sulodexide – a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(6):1245–1253. doi:10.1111/bcp.12722.; Кузнецова И.В. Роль преконцепционной эндотелиальной дисфункции в развитии акушерских осложнений. Медицинский алфавит. 2019;1(1):53–58. doi:10.33667/2078-5631-2019-1-1(376)-53-58.; https://www.med-sovet.pro/jour/article/view/5572

الاتاحة: https://www.med-sovet.pro/jour/article/view/5572
https://doi.org/10.21518/2079-701X-2020-3-68-73

المؤلفون: M. Vinogradova A., М. Виноградова А.

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2017); 194-197 ; Медицинский Совет; № 20 (2017); 194-197 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-20

مصطلحات موضوعية: anemia, iron deficiency, pregnancy, postpartum period, ferric carboxymaltose, анемия, железодефицит, беременность, послеродовой период, карбоксимальтозат железа

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2254/2238; Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol, 2016 Jan, 91(1): 31-38.; Achebe ММ and Gafter-Gvili А How I treat anemia in pregnancy: iron, cobalamin, and folate. BLOOD, 2017 Feb 23, 129(8): 940-949; Виноградова М.А., Федорова Т.А., Рогачевский О.В. Анемия при беременности: алгоритмы диагностики и лечения железодефицита. Акушерство и гинекология, 2014, 8: 138-143.; McLean E et al. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr, 2009, 12(4): 444-454.; Milman N. Prepartum anaemia: prevention and treatment. Ann Hematol, 2008, 87: 949–959.; Виноградова M.А., Федорова Т.А. Железодефицитная анемия во время беременности – профилактика и лечение. Медицинский совет, 2015, 9: 78-82.; Breymann C. et al. Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region. Journal of perinatal medicine, 2011, 39(2): 113-121.; The Obstetric Hematology Manual edited by Sue Pavord, Beverley Hunt. Cambridge University Press, 2010: 13-27.; Arnold DL, Williams MA, Miller RS, Qiu C & Sorensen TK. Maternal iron deficiency anaemia is associated with an increased risk of abruption placentae – a retrospective case control study. J Obstet Gynaecol Res, 2009, 35, 446-452.; Allen LH. Biological mechanisms that might underlie iron’s effects on fetal growth and preterm birth. Am J Clin Nutr, 2001, 131: 581S–9S.; Scholl TO and Reilly T Anemia, Iron and Pregnancy Outcome. Am J Clin Nutr, 2000, 130: 443S–447S.; Beard JL. Why iron deficiency is important in infant development. J Nutr, 2008, 138: 2534-2536.; Виноградова М.А., Федорова Т.А., Рогачевский О.В. Влияние железодефицитной анемии на исходы беременности. Акушерство и гинекология, 2015, 7: 78-82.; Breymann C et al. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Archives of gynecology and obstetrics, 2010, 282(5): 577-580.; Баранов И.И., Дегтярева Е.И., Апресян С.В. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии, 3-е изд. М., 2016.; Моисеев С.В. Железа карбоксимальтозат (Феринжект) – новый внутривенный препарат для лечения железодефицитной анемии. Клин фармакол тер, 2012, 21(2): 48-53.; Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program, 2010, 2010(1): 338-47.; Moore R, Gaskell H, Rose P, Allan J. Metaanalysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord, 2011, 1: 4.; Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med, 2012, 40(5): 469-74.; Breymann C, Milman N, Mezzacasa A, Bernard R and Dudenhausen J, on behalf of the FER-ASAP investigators Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, openlabel, randomized controlled trial (FER-ASAP). J Perinat Med, 2016, Jun 8. pii: /j/jpme.ahead-ofprint/jpm-2016-0050/jpm-2016-0050.xml. doi:10.1515/jpm-2016-0050.; Froessler B. et al. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC pregnancy and childbirth, 2014, 14(1): 115.; Breymann C et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. International Journal of Gynecology & Obstetrics, 2008, 101(1): 67-73.; Виноградова М.А. Карбоксимальтозат железа в лечении анемии в акушерско-гинекологической практике. Клиническая фармакология и терапия, 2014, 23(4): 36-40.; Vinogradova MA, Fedorova TA, Strelnikova EV et al. Anemia during the Pregnancy: The Management and Outcomes Depending on the Etiology Blood, 2014, 56th ASH Annual Meeting Abstracts, December 6-9, 2014, San Francisco, California. Blood, 2014, 124: 4830.; Vinogradova MA, Fedorova TA, Rogachevsky OV. Iron deficiency anemia during pregnancy: the treatment approaches and outcomes. British Journal of Haematology, 2015, 169(suppl 1): 100-101.; Шевелева Г.А., Федорова Т.А., Дубровина Н.В., Сокур Т.Н., Бакуридзе Э.М. Нарушение вегетативной регуляции у беременных с железодефицитной анемией и способы ее коррекции. Акушерство и гинекология, 2017, 6: 35-40.; Радзинский В.Е., Ордиянц И.М., Побединская О.С. Железодефицитная анемия как фактор риска плацентарной недостаточности и перинатальных осложнений. Акушерство и гинекология, 2016, 12: 125-130.; https://www.med-sovet.pro/jour/article/view/2254

الاتاحة: https://www.med-sovet.pro/jour/article/view/2254
https://doi.org/10.21518/2079-701X-2017-20-194-197

المؤلفون: М. Виноградова А., Т. Фёдорова А., T. Fedorova A.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2015); 78-83 ; Медицинский Совет; № 9 (2015); 78-83 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2015-9

مصطلحات موضوعية: анемия, беременность, дефицит железа, полимальтозный комплекс гидроксида железа, anemia, pregnancy, iron deficiency, iron(III)-hydroxide polymaltose complex

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/250/250; WHO Iron Deficiency Anaemia: Assessment, Prevention and Control. WHO/NHD/01.3, World Health Organization, 2001, Geneva, Switzerland.; Sifakis S and Pharmakides G. Anemia in pregnancy. Ann. N. Y. Acad. Sci., 2000, 900: 125-36.; Ramsey M, James D & Steer P. Normal Values in Pregnancy, 2nd edn. WB Saunders, London, 2000.; Coad J, Conlon C. Iron deficiency in women: assessment, causes and consequences. Current opinion in clinical nutrition and metabolic care. 2011, 14, 625-634.; Friedman AJ et al. Iron deficiency anemia in women across the life span. Journal of women's health, 2012, 21: 1282-1289.; The Obstetric Hematology Manual edited by Sue Pavord, Beverley Hunt. Cambridge University Press 2010. P. 13-27.; Ren A, Wang J, Ye RW, Li S, Liu JM, Li Z (2007). Low first trimester hemoglobin and low birth weight, preterm birth and small for gestational age new-borns. Int J Gynaecol Obstet, 98: 124-128.; Koller O (1982). The clinical significance of hemodilution during pregnancy. Obstet Gynecol Surv, 37:649-652.; Breymann Ch et al. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet , 2010, 282: 577-580.; Milman N (2006). Iron and pregnancy - a delicate balance. Ann Hematol, 85: 559-565.; Bothwell TH (2000). Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr, 72: 257-264.; Milman N, Byg K-E, Ovesen L (2000). Iron status in Danes updated 1994. II. Prevalence of iron deficiency and iron overload on 1319 women aged 40-70 years. Influence of blood donation, alcohol intake, and iron supplementation. Ann Hematol, 79: 612-621.; Milman N. Prepartum anaemia: prevention and treatment. Ann Hematol, 2008, 87: 949-959.; Milman N (2006). Iron prophylaxis in pregnancy-general or individual and in which dose? Ann Hematol, 85: 821-828 doi:10.1007/ s00277-006-0145-x.; Milman N, Bergholdt T, Byg K-E, Eriksen L, Hvas A-M (2007). Reference intervals for haemato-logical variables during normal pregnancy and postpartum in 433 healthy Danish women. Eur J Haematol, 79: 39-46.; Makrides M, Crowther CA, Gibson RA, Gibson RS, Skeaff CM (2003). Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomised controlled trial. Am J Clin Nutr, 78: 145-153.; Milman N, Bergholt T, Eriksen L, Byg K-E, Graudal N, Pedersen P, Hertz J (2005). Iron prophylaxis during pregnancy - how much iron is needed? A randomised, controlled study of 20 to 80 mg ferrous iron daily to pregnant women. Acta Obstet Gynecol Scand, 84: 238-247.; Skikne B, Baynes RD (1994). Iron absorption. In: Brock JH, Halliday JW, Pippard MJ, Powell LW (eds) Iron metabolism in health and disease. Saunders, London, pp 151-187.; Milman N, Graudal N, Nielsen OJ, Agger AO (1997). Serum erythropoietin during normal pregnancy: relationship to hemoglobin and iron status markers and impact of iron supplementation in a longitudinal, placebo-controlled study on 118 women. Int J Hematol, 66: 159-168.; Beris P, Maniatis A on behalf of the NATA working group on intravenous iron therapy (2007). Guidelines on intravenous iron supplementation in surgery and obstetrics/gynecology. TATM transfus Altern Transfus Med 9 (Suppl 1): 29.; Adamson JW. Fauci AS. Kasper Dl, et al. Iron deficiency and other hypoproliferative anaemias. In: Braunwald E, editor; Harrison's Principles of Internal Medicine.15th edition. Mc Graw Hill; 2001. pp 660-66.; Sharma N. Iron absorption: IPC therapy is superior to conventional iron salts. Obstet Gynecol., 2001: 515-19.; Toblli JE, Cao G, Oliveri L, Angerosa M. Effects of iron polymaltose complex, ferrous fumarate and ferrous sulfate treatments in anemic pregnant rats, their fetuses and placentas. Inflamm Allergy Drug Targets, 2013, 12(3): 190-8.; Badhwar VR, Rao S, Fonseca MM. Comparative efficacy and safety of iron polymaltose+folic acid and oral ferrous fumarate in the treatment of adult patients with iron deficiency anemia. Indian Med Gazette, 2003, 136: 296-301.; Patkar VD, Patkar S, Khandeparker PS, Dingankar NS, Shetty RS. Evaluation of efficacy and tolerability of iron (III) - hydroxide poly-maltose complex tablets in the treatment of iron deficiency anaemia in women. Indian Med Gazette, 2001, 135: 306-309.; Saha L, Pandhi P, Gopalan S, Malhotra S and Saha PK. Comparison of Efficacy, Tolerability, and Cost of Iron Polymaltose Complex With Ferrous Sulphate in the Treatment of Iron Deficiency Anemia in Pregnant Women. MedGenMed, 2007, 9(1): 1.; McCord JM. Iron, free radicals, and oxidative injury. Semin Hematol., 1998, 35: 5-12.; Christoph P, Schuller C, Studer H et al. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med, 2012, 13, 40(5), 469-474.; Reveiz L, Gyte GML, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy (Review), Cochrane library, 2011.; Beris P, Maniatis A, on behalf of the NATA working group on intravenous iron therapy (2007) Guidelines on intravenous iron supplementation in surgery and obstetrics/gynecology. TATM transfus Altern Transfus Med 9 (Suppl 1): 29.; https://www.med-sovet.pro/jour/article/view/250

الاتاحة: https://www.med-sovet.pro/jour/article/view/250
https://doi.org/10.21518/2079-701X-2015-9-78-83